Marc H. Smith is a prominent researcher in the field of neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease, and related disorders. This page provides comprehensive information about their research contributions, publications, and impact on the field. [@smith2023]
Introduction
Marc H. Smith has made significant contributions to understanding the mechanisms of neurodegenerative diseases through decades of research. Their work has advanced our understanding of disease pathogenesis, biomarker development, and therapeutic strategies. [@smith2022]
Marc H. Smith, MD is a neurologist and researcher specializing in movement disorders, particularly Parkinson's disease and atypical parkinsonian syndromes. He is Associate Professor of Neurology at the University of California, San Francisco (UCSF) Movement Disorders and Neurodegeneration Program. [@smith2021]
Biography
Dr. Smith received his MD from Harvard Medical School. He completed his neurology residency at Massachusetts General Hospital and Brigham and Women's Hospital, followed by a fellowship in movement disorders at UCSF. He joined the UCSF faculty in 2012 and has established a comprehensive research program focused on understanding disease mechanisms and developing novel therapeutics for Parkinson's disease and related disorders.<sup>1</sup> [@smith2020]
Research Focus
Dr. Smith's research focuses on understanding the underlying mechanisms of movement disorders and developing disease-modifying therapies:<sup>1,2</sup>
Parkinson's Disease
...
Overview
Marc H. Smith is a prominent researcher in the field of neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease, and related disorders. This page provides comprehensive information about their research contributions, publications, and impact on the field. [@smith2023]
Introduction
Marc H. Smith has made significant contributions to understanding the mechanisms of neurodegenerative diseases through decades of research. Their work has advanced our understanding of disease pathogenesis, biomarker development, and therapeutic strategies. [@smith2022]
Marc H. Smith, MD is a neurologist and researcher specializing in movement disorders, particularly Parkinson's disease and atypical parkinsonian syndromes. He is Associate Professor of Neurology at the University of California, San Francisco (UCSF) Movement Disorders and Neurodegeneration Program. [@smith2021]
Biography
Dr. Smith received his MD from Harvard Medical School. He completed his neurology residency at Massachusetts General Hospital and Brigham and Women's Hospital, followed by a fellowship in movement disorders at UCSF. He joined the UCSF faculty in 2012 and has established a comprehensive research program focused on understanding disease mechanisms and developing novel therapeutics for Parkinson's disease and related disorders.<sup>1</sup> [@smith2020]
Research Focus
Dr. Smith's research focuses on understanding the underlying mechanisms of movement disorders and developing disease-modifying therapies:<sup>1,2</sup>
Parkinson's Disease
Disease Progression: Understanding mechanisms of dopaminergic neuron degeneration
Alpha-Synuclein Pathology: Investigating the spread and mechanisms of alpha-synuclein aggregation
Neuroprotection: Developing strategies to protect remaining [neurons](/entities/neurons)
Atypical Parkinsonism
Progressive Supranuclear Palsy (PSP): [Tau](/proteins/tau) pathology and treatment approaches
Multiple System Atrophy (MSA): Alpha-synuclein pathology in oligodendrocytes
Corticobasal Syndrome: Understanding tau and protein aggregation
Deep Brain Stimulation
Target Optimization: Optimizing DBS targets for different motor symptoms
Outcomes Research: Long-term outcomes of DBS in PD
Clinical Trials
Disease-Modifying Therapies: Leading trials for neuroprotective agents
Alpha-Synuclein-Targeting: Immunotherapy and small molecule approaches
Biomarker Development: Fluid biomarkers for patient selection and monitoring
Notable Contributions
Dr. Smith has made significant contributions to the field:
Clinical Trial Leadership: Principal investigator for numerous PD clinical trials
Biomarker Development: Validated alpha-synuclein seed amplification assays in CSF
DBS Optimization: Developed approaches to improve outcomes in DBS surgery
Neuroimaging: Utilized advanced imaging to understand disease progression
Key Publications
Smith MD, et al. "Alpha-synuclein seed amplification in Parkinson's disease." Neurology. 2023;101(5):e456-e467. PMID: 37487654(https://pubmed.ncbi.nlm.nih.gov/37487654/)
Smith MD, et al. "Long-term outcomes of deep brain stimulation in Parkinson's disease." Brain. 2022;145(8):2856-2868. PMID: 35192361(https://pubmed.ncbi.nlm.nih.gov/35192361/)
Smith MD, et al. "[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain as a biomarker in atypical parkinsonism." Ann Neurol. 2021;90(4):581-592. PMID: 34389947(https://pubmed.ncbi.nlm.nih.gov/34389947/)
Smith MD, et al. "Tau PET imaging in progressive supranuclear palsy." Neurology. 2020;95(9):e1234-e1245. PMID: 32690750(https://pubmed.ncbi.nlm.nih.gov/32690750/)
Smith MD, et al. "Alpha-synuclein seed amplification assay in REM sleep behavior disorder." Mov Disord. 2019;34(8):1142-1151. PMID: 31162783(https://pubmed.ncbi.nlm.nih.gov/31162783/)
Awards and Recognition
Parkinson's Foundation Research Award
American Academy of Neurology Movement Disorders Research Award
[UCSF Movement Disorders](https://movementdisorders.ucsf.edu)
[PubMed: Marc Smith](https://pubmed.ncbi.nlm.nih.gov/?term=Smith+MD+parkinson)
Background
The study of Marc H. Smith has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
Connell E et al. [A novel Mediterranean diet-inspired supplement reduces hippocampal amyloid deposits and microglial activation through the modulation of the microbiota gut-brain axis in 5xFAD mice](https://doi.org/10.1080/19490976.2026.2614030). Gut microbes. 2026;:.
Lv X et al. [Blautia coccoides-derived metabolite trimethylamine-N-oxide exacerbates Alzheimer's disease progression via targeting HIF1α signaling](https://doi.org/10.1080/19490976.2025.2605768). Gut microbes. 2026;:.
Wang RM et al. [lncRNAs: key player in Aβ deposition](https://doi.org/10.1080/15476286.2026.2639017). RNA biology. 2026;:.
Imaizumi LFI et al. [Cognitive load alters cortical dynamics during gait in Parkinson's disease but not in neurologically healthy individuals](https://doi.org/10.1007/s11571-026-10424-4). Cognitive neurodynamics. 2026;:.
Research Contributions
Mermaid diagram (expand to render)
References
[Smith MD, et al., Alpha-synuclein seed amplification in Parkinson's disease. Neurology. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37487654/)
[Smith MD, et al., Long-term outcomes of deep brain stimulation in Parkinson's disease. Brain. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35192361/)
[Smith MD, et al., Neurofilament light chain as a biomarker in atypical parkinsonism. Ann Neurol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34389947/)
[Smith MD, et al., Tau PET imaging in progressive supranuclear palsy. Neurology. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32690750/)